home / stock / aim / aim news

AIM News and Press, AIM ImmunoTech Inc. From 11/21/23

Stock Information
Company Name: AIM ImmunoTech Inc.
Stock Symbol: AIM
Market: NYSE
Website: aimimmuno.com
Menu
AIM AIM Quote AIM Short AIM News AIM Articles AIM Message Board
Get AIM Alerts

News, Short Squeeze, Breakout and More Instantly...
AIM - AIM ImmunoTech Completes Treatment of Last Subject in Phase 2 Study Evaluating Ampligen® for the Treatment of Post-COVID Conditions

No severe adverse events reported to date Topline data expected as early as Q1 2024 OCALA, Fla., Nov. 21, 2023 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today announced the last subject has completed...
AIM - AIM ImmunoTech Inc. (AIM) Q3 2023 Earnings Call Transcript

2023-11-15 13:39:04 ET AIM ImmunoTech Inc. (AIM) Q3 2023 Earnings Call Transcript November 15, 2023 08:00 AM ET Company Participants Thomas Equels - Executive Vice Chairman, Chief Executive Officer and President Christopher McAleer - Scientific Officer Conferen...

AIM - AIM ImmunoTech GAAP EPS of -$0.16 misses by $0.04

2023-11-15 07:37:48 ET More on AIM ImmunoTech Seeking Alpha’s Quant Rating on AIM ImmunoTech Historical earnings data for AIM ImmunoTech Financial information for AIM ImmunoTech For further details see: AIM ImmunoTech GAAP EPS of -$0.16 misses by $...

AIM - AIM ImmunoTech Reports Third Quarter 2023 Financial Results and Provides Clinical Pipeline Update

– Highlights continued execution across Ampligen ® clinical development programs – Company is well positioned to achieve multiple value-driving milestones during remainder of 2023 and 2024 – Will host conference call and webcast today, November 15 ...
AIM - Notable earnings before Wednesday's open

2023-11-14 10:52:25 ET Major earnings expected before the bell on Wednesday include: JD.com ( JD ) Tencent Holdings ( OTCPK:TCEHY ) Target ( TGT ) XPeng ( XPEV ) ZIM Integrated Shipping Services ( ZIM ) For further details see: Notable ear...

AIM - AIM ImmunoTech Announces Publication of Data from Roswell Park Comprehensive Cancer Center Phase 1 Study Evaluating Ampligen® as a Component of a Chemokine-Modulating (CKM) Regimen in Metastatic Triple-Negative Breast Cancer

OCALA, Fla., Nov. 14, 2023 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today announced the publication of results from the Phase 1 study at Roswell Park Comprehensive Cancer Center in patients with metastatic triple...

AIM - AI-Media to Showcase Cutting-Edge Captioning Tech at Global Media Congress

ABU DHABI, United Arab Emirates, Nov. 13, 2023 (GLOBE NEWSWIRE) -- The Global Media Congress is scheduled to take place in Abu Dhabi, UAE, from November 14 to 16, 2023, following its successful 2022 edition. This year, AI-Media ,  will play a central role as the live caption and ...
AIM - Long Cast Advisers Q3 2023 Letter

2023-11-11 01:30:00 ET Summary Long Cast Advisers, LLC, is an independent-registered investment adviser investing on behalf of individuals, family offices and endowments. It is concentrated on long-term investing, focused on small-cap companies. Long Cast Advisors achieved cumulat...

AIM - AIM ImmunoTech to Discuss Third Quarter 2023 Financial Results on November 15, 2023 and Host Conference Call and Webcast

OCALA, Fla., Nov. 09, 2023 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”), announced today that management will host a conference call and webcast to discuss the Company’s Q3 2023 operational and financial r...

AIM - AIM ImmunoTech Announces Encouraging Translational Data from Phase 2 Study Evaluating Ampligen® for the Treatment of Advanced Recurrent Ovarian Cancer

Data presented at the Society for Immunotherapy of Cancer (SITC) 38 th Annual Meeting Longitudinal comparison of biomarkers in tumor microenvironment showed a gradual, durable response over time in T lymphotactic CXCR3 ligands and cytolytic factors Phase 2 study ongo...
Previous 10 Next 10